A Wealth of Experience

At RTI Health Solutions, we have collaborated with our clients on more than 150 projects researching cutaneous diseases, cutaneous treatments, and complications and comorbidities of cutaneous diseases. Our experience includes:

- Acne
- Alopecia
- Atopic dermatitis
- Dry skin
- Eczema
- Herpes
- Psoriasis
- Skin cancer
  - Basal cell carcinoma
  - Squamous cell carcinoma
  - Melanoma
- Stevens-Johnson syndrome
- Systemic lupus erythematosus
- Toxic epidermal necrolysis
- Warts

Types of Projects

We have implemented studies to help our clients develop strategies in the dermatology market and develop and gain market access for products to treat cutaneous diseases and complications arising from treatment of cutaneous illnesses. Recent projects have included:

- Epidemiology of disease
- Retrospective analyses using longitudinal databases
- Patient-reported outcomes (PRO) instrument development, psychometric evaluation, and validation
- Decision-analytic modeling to examine
  - Cost-effectiveness
  - Budget impact
- Meta-analyses
- Gap analyses for HEOR strategy planning
- Measurement of patients’ benefit-risk preferences and willingness to pay for treatment
- Economic burden of illness studies
- Systematic literature reviews
- Global value dossiers
- Value communication and reimbursement strategies
- Q-TWiST analyses (quality-adjusted time without symptoms or toxicities)
- Exploratory analyses of clinical trial data
- Abstract and manuscript development
See How We’ve Helped Others

Conjoint Analysis to Assess Patients’ Preferences and Willingness to Pay for Treatment
We implemented a conjoint analysis study to estimate how the severity and size of psoriasis lesions affect patients’ preferences and willingness to pay for treatments. The study asked patients about lesion severity, percentage of body surface area (BSA) covered by lesions, type of treatment, discomfort or pain from injection treatments, risk of serious lung infection, and monthly out-of-pocket cost. The study found that patients are willing to pay substantial amounts (up to $487 per month) to reduce lesion severity and percentage of BSA covered by lesions. Study results were published in *Journal of Dermatological Treatment*, 2011;22(5):266-75.

Economic Threshold Model for a Treatment for Atopic Dermatitis
We developed an economic threshold model to explore the potential clinical and economic value of a new product in development for the treatment of atopic dermatitis. The model was designed to evaluate the effects of using the new product in a variety of populations to demonstrate safety advantages compared to existing treatments. Additionally, the model allowed us to evaluate the effects of using the new product on sensitive parts of the body and on a larger percentage of body surface area compared with existing treatments. Our client was able to use the model to support early decisions about relevant comparators, pricing, and the design of phase 3 clinical trials for the new product.

Burden of Chronic Idiopathic Urticaria
We conducted an observational, non-interventional, multinational, multicenter study to identify and quantify the humanistic and economic burden of illness of chronic idiopathic urticaria (CIU) patients. The study yielded key data on the HRQOL and financial burden experienced by patients with CIU; providing real-world data to support the value proposition for treatment of CIU. Study results were published in *Allergy*, 2014 Jan;69(Suppl 99):122.

Daily Diary to Assess Psoriasis-Related Symptoms
We collaborated with a major pharmaceutical company to conduct a psychometric evaluation of phase 3 clinical trial data in support of a daily diary designed to measure symptoms related to psoriasis. In addition, we developed a PRO dossier to support FDA review of the diary. In January 2015, the FDA approved a label claim based on the diary. The psychometric evaluation was presented at the ISPOR 19th Annual International Meeting in November 2014.

Selected Publications and Presentations By Our Staff


Hawe E, Vickers AD, Mallya UG, McBride DW, Capkun-Niggli G, Olson M, Thorlund K. Secukinumab 300mg demonstrates highest probability of efficacy than other biologics in psoriasis: indirect comparison. Poster presented at the 23rd European Academy of Dermatology and Venerology Congress; 2014 Oct 8; Amsterdam, The Netherlands.


